Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #37018
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Share Price
$0.25974701
Last synced: 2025-01-06
Market Cap
$2.04M
Change (1 day)
0.74%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Stock price history for Acticor Biotech SAS (ALACT)
Highest end of day price: $0.26 on 2025-01-01

Lowest end of day price: $7.56 on 2021-11-01
Stock price history of Acticor Biotech SAS from 2021 to 2026
Annual Stock Price Performance
Year Performance
2025 -4.45%
2024 -91.43%
2023 -58.60%
2022 31.92%
2021 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$512.61 30.37%
US
$983.59 29.96%
NL
$122.35 -10.30%
AU
$142.51 496.78%
US
$698.66 1.47%
CH